Diamond BiofundTPE:6901 16 EBIT per Share is NT$-1.37 as of Dec. 2025. GuruFocus rates TPE:6901 with a GF Score™ of 16/100. The stock has 2 warning signs investors should review. Among 494 Asset Management companies, Diamond Biofund ranks worse than 62.15% on this metric.
Diamond Biofund's EBIT per Share for the
three
months ended in Dec. 2025 was NT$-0.02.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1.37.
During the past 3 years, the average EBIT per Share Growth Rate was -1.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 4.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Diamond Biofund's EBIT per Share or its related term are showing as below:
TPE:6901'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -25.8 Med: -12.1 Max: 19.9
Current: -1.1
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Diamond Biofund was 19.90% per year. The lowest was -25.80% per year. And the median was -12.10% per year.
TPE:6901's 3-Year EBIT Growth Rate is ranked worse than 62.15% of 494
companies
in the Asset Management industry
Industry Median: 10.6
vs TPE:6901: -1.10
Diamond Biofund's EBIT for the
three
months ended in Dec. 2025 was NT$-13.92 Mil.
Diamond Biofund (TPE:6901) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Diamond Biofund EBIT per Share Related Terms
Diamond Biofund EBIT per Share Historical Data
* Premium members only.
The historical data trend for Diamond Biofund's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-1.37
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diamond Biofund (TPE:6901) has a EBIT per Share of NT$-1.37 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Diamond Biofund and its competitors. According to the industry distribution chart, Diamond Biofund ranks #307 out of 494 companies in the Asset Management industry, placing it in the top 62.1%.
Is Diamond Biofund's EBIT per Share too high?
Diamond Biofund's current EBIT per Share is NT$-1.37. Based on the distribution chart, Diamond Biofund ranks #307 out of 494 companies in the Asset Management industry, which is below the industry midpoint. Overall, Diamond Biofund has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Diamond Biofund's EBIT per Share compare to BLK and BX?
According to the Asset Management industry distribution chart, Diamond Biofund ranks #307 out of 494 companies for EBIT per Share. This places Diamond Biofund in the lower half of its industry. The industry median EBIT per Share is 10.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for an Asset Management company?
The median EBIT per Share among Asset Management companies is 10.60, based on 494 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Diamond Biofund and its competitors. For the Asset Management industry, the median EBIT per Share is 10.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diamond Biofund's current EBIT per Share is NT$-1.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamond Biofund stock overvalued right now?
Diamond Biofund (TPE:6901) has a current EBIT per Share of NT$-1.37. The current EBIT per Share is NT$-1.37. Diamond Biofund's overall GF Score™ is 16/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Diamond Biofund (TPE:6901), the current EBIT per Share is NT$-1.37 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Diamond Biofund Inc is a sustainable biotech venture capital that focuses on the field of biotechnology and medical investment, targeting competitive investment targets, including new drug research and development, high-end medical equipment, medical service technology, medical access, agricultural biotechnology.
16GF Score
Get the complete analysis for TPE:6901
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6901 has been successfully added to your 
